BPDCN marker triad

IT’S AS SIMPLE AS
CD123, CD4, CD56*

Cell surface markers play a crucial role in differentiating hematologic cancers.1,2

Read more

BPDCN hematologic cancer

UNDERSTANDING BPDCN

An aggressive and deadly hematologic cancer can now be identified.3

Read more

BPDCN markers

BPDCN: DIAGNOSIS AND THE STATE OF
TREATMENT TODAY

Currently, BPDCN can be diagnosed but there are no approved therapies or an accepted standard of care for patients.3

Read more

A HEMATOLOGIC CANCER THAT CAN BE DANGEROUSLY UNSEEN

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a newly recognized hematologic cancer that has remained underdetected, primarily because of overlapping presentations and morphologically minute distinctions between other malignancies. Now, using a newly discovered marker triad, diagnosis can be as simple as CD123, CD4, CD56.1,3

BPDCN is an aggressive and deadly hematologic cancer and may present with features similar to AML, NHL, ALL, MDS, and CMML, as well as other malignancies with skin manifestations. Currently, there are no approved therapies for BPDCN, and there is no standard of care for patients.3-6

Now, the identification of CD123 in conjunction with CD4 and CD56 is helping to differentiate BPDCN from other hematologic malignancies. CD123 is a rapidly emerging target for therapeutic research in several hematologic cancers.4

Stemline Therapeutics, Inc. is committed to advancing therapeutic research to help patients with BPDCN.

AML = acute myeloid leukemia; NHL = non-Hodgkin’s lymphoma; ALL = acute lymphoblastic leukemia; MDS = myelodysplastic syndrome; CMML = chronic myelomonocytic leukemia.
*BPDCN diagnosis can include other markers, such as TCL1 and CD303 (BDCA2).7

References:

  1. Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98-111.
  2. FitzGerald DJ. Targeted diphtheria toxin to treat BPDCN. Blood. 2014;124(3):310-312.
  3. Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279-289.
  4. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
  5. Laribi K, Denizon N, Besançon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357-1367.
  6. León-Martínez G, Meillón-García L, Morales-Polanco M, Soler-Montecinos L, Ortiz-Hidalgo C. Unusual morphologic presentations of blastic plasmacytoid dendritic cell neoplasm: report of two cases misdiagnosed as melanoma and leprosy. Int J Surg Pathol. 2014;22(1):76-82.
  7. Reichard KK. Blastic plasmacytoid dendritic cell neoplasm: how do you distinguish it from acute myeloid leukemia? Surg Pathol Clin. 2013;6(4):743-765.